Rudolph Navari on Olanzapine for Preventing Nausea and Vomiting
Rudolph Navari, professor of Medicine at Indiana University School of Medicine - South Bend, discusses the effectiveness of olanzapine (Zyprexa) in preventing nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Rudolph Navari, professor of Medicine at Indiana University School of Medicine South Bend, discusses the effectiveness of olanzapine (Zyprexa) in preventing nausea and vomiting in patients receiving highly emetogenic chemotherapy.
In a phase III, randomized, double-blind study, Navari added olanzapine to a standard antiemetic regimen and compared it to a placebo with the same antiemetic regimen.
The standard antiemetic regimen supplemented with olanzapine was significantly effective in preventing nausea and vomiting. This was the first study that used nausea as a primary endpoint.
Olanzapine is currently approved by the FDA as an antipsychotic, but not for the prevention of nausea.
Navari says clinical practice should change to use olanzapine with a standard antiemetic regimen for patients receiving highly emetogenic chemotherapy.
Nursing Perspectives on Managing Toxicities With ADCs in Metastatic Gastric and Breast Cancers
September 1st 2022In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.
Increasing Awareness of Audiovestibular Adverse Events From Immune Checkpoint Inhibitors
July 16th 2024Oncology nurses play a critical role in identifying and managing rare audiovestibular complications associated with immune checkpoint inhibitors to prevent permanent hearing loss and improve patients' quality of life.
